The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Willkie Farr & Gallagher has advised US dermatology company Stiefel Laboratories on its $3.6bn (£2.5bn) takeover by pharmaceutical giant GlaxoSmithKline (GSK)
Willkie Farr & Gallagher has advised US dermatology company Stiefel Laboratories on its $3.6bn (£2.5bn) takeover by pharmaceutical giant GlaxoSmithKline (GSK), in what is one of the biggest M&A transactions to hit the market in recent months.
Corporate partners William Grant and Greg Astrachan began advising Stiefel in 2006 following a beauty parade. They have since advised the company on a number of significant transactions including the $500m (£340m) investment by Blackstone in 2007 and its 2008 acquisition of Barrier Therapeutics.
Astrachan said: “There were three big M&A deals announced last Monday. My hope is that it’s a bellwether of future activity.” GSK will acquire the total share capital of Stiefel for $2.9bn (£1.9bn) and assume $400m (£300m) of net debt upon closing. A potential further $300m (£200m) cash payment is contingent on future performance.
Cleary Gottlieb Steen & Hamilton advised GSK. The team was led by New York-based corporate partner Benet O’Reilly, assisted by teams across antitrust, employee benefits, environmental, international diligence, IP, international regulatory, real estate and tax based in Brussels, New York and Washington DC.